Literature DB >> 19098321

Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma.

Holly L Rosenzweig1, Tatsushi Kawaguchi, Tammy M Martin, Stephen R Planck, Michael P Davey, James T Rosenbaum.   

Abstract

PURPOSE: Nucleotide oligomerization domain-2 (NOD2) plays an important role in innate immunity to sense muramyl dipeptide (MDP), a component of bacterial cell walls. Notably, NOD2 is linked to eye inflammation because mutations in NOD2 cause a granulomatous type of uveitis called Blau syndrome. A mouse model of NOD2-dependent ocular inflammation was employed to test the role of a cytokine strongly implicated in granuloma formation, IFN-gamma, in order to gain insight into downstream functional consequences of NOD2 activation within the eye triggering uveitis.
METHODS: Mice deficient in IFN-gamma, NOD2, or CD11b and their wild-type controls were treated with intravitreal injection of MDP in the presence or absence of IFN-gamma. IFN-gamma production in the eye was measured by ELISA. The intravascular inflammatory response within the iris was quantified by intravital microscopy.
RESULTS: NOD2 activation resulted in the production of IFN-gamma within the eye. Deficiency in IFN-gamma diminished the development of MDP-induced uveitis, indicating its crucial role in downstream inflammatory events triggered by NOD2. Moreover, exogenous IFN-gamma markedly exacerbated MDP-induced ocular inflammation in a NOD2-dependent mechanism. The potential of IFN-gamma to enhance inflammation required the adhesion molecule CD11b because CD11b-deficient mice failed to show the synergistic effects of IFN-gamma and MDP cotreatment on adhering and infiltrating cells.
CONCLUSIONS: IFN-gamma was identified as a downstream mediator of NOD2-driven inflammation and the capacity of IFN-gamma in vivo to enhance the inflammatory potential of NOD2 was demonstrated. Extrapolation of these findings in mice suggests that the dysregulation of IFN-gamma may occur in patients with Blau syndrome, thereby contributing to the granulomatous nature of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19098321      PMCID: PMC3089593          DOI: 10.1167/iovs.08-2756

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  45 in total

Review 1.  Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium.

Authors:  Dietmar Vestweber
Journal:  Immunol Rev       Date:  2007-08       Impact factor: 12.988

Review 2.  Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation.

Authors:  Xiaoyu Hu; Janice Chen; Lu Wang; Lionel B Ivashkiv
Journal:  J Leukoc Biol       Date:  2007-05-14       Impact factor: 4.962

3.  RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs.

Authors:  Jong-Hwan Park; Yun-Gi Kim; Christine McDonald; Thirumala-Devi Kanneganti; Mizuho Hasegawa; Mathilde Body-Malapel; Naohiro Inohara; Gabriel Núñez
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

4.  The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens.

Authors:  Yen-Michael S Hsu; Yongliang Zhang; Yun You; Donghai Wang; Hongxiu Li; Omar Duramad; Xiao-Feng Qin; Chen Dong; Xin Lin
Journal:  Nat Immunol       Date:  2006-12-24       Impact factor: 25.606

5.  MDP-induced interleukin-1beta processing requires Nod2 and CIAS1/NALP3.

Authors:  Qilin Pan; John Mathison; Colleen Fearns; Vladimir V Kravchenko; Jean Da Silva Correia; Hal M Hoffman; Koichi S Kobayashi; John Bertin; Ethan P Grant; Anthony J Coyle; Fayyaz S Sutterwala; Yasunori Ogura; Richard A Flavell; Richard J Ulevitch
Journal:  J Leukoc Biol       Date:  2007-04-02       Impact factor: 4.962

6.  Pediatric granulomatous arthritis: an international registry.

Authors:  Carlos D Rosé; Carine H Wouters; Silvia Meiorin; Trudy M Doyle; Michael P Davey; James T Rosenbaum; Tammy M Martin
Journal:  Arthritis Rheum       Date:  2006-10

7.  Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency.

Authors:  Shao Bo Su; Rafael S Grajewski; Dror Luger; Rajeev K Agarwal; Phyllis B Silver; Jun Tang; Jingsheng Tuo; Chi-Chao Chan; Rachel R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

8.  Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis.

Authors:  H L Rosenzweig; M M Jann; T T Glant; T M Martin; S R Planck; W van Eden; P J S van Kooten; R A Flavell; K S Kobayashi; J T Rosenbaum; M P Davey
Journal:  J Leukoc Biol       Date:  2009-01-07       Impact factor: 4.962

9.  Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide.

Authors:  Mark Windheim; Christine Lang; Mark Peggie; Lorna A Plater; Philip Cohen
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

10.  IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2.

Authors:  Sabine Tötemeyer; Mark Sheppard; Adrian Lloyd; David Roper; Christopher Dowson; David Underhill; Peter Murray; Duncan Maskell; Clare Bryant
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

View more
  14 in total

1.  NOD1 and NOD2 receptors in mrigal (Cirrhinus mrigala): inductive expression and downstream signalling in ligand stimulation and bacterial infections.

Authors:  Banikalyan Swain; Madhubanti Basu; Mrinal Samanta
Journal:  J Biosci       Date:  2013-09       Impact factor: 1.826

Review 2.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

3.  Endotoxin-induced uveitis is primarily dependent on radiation-resistant cells and on MyD88 but not TRIF.

Authors:  J Kezic; S Taylor; S Gupta; S R Planck; H L Rosenzweig; J T Rosenbaum
Journal:  J Leukoc Biol       Date:  2011-05-24       Impact factor: 4.962

4.  Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus.

Authors:  Travis Kochan; Anuj Singla; Joaquin Tosi; Ashok Kumar
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

5.  TLR2 mediates the innate response of retinal Muller glia to Staphylococcus aureus.

Authors:  Nazeem Shamsuddin; Ashok Kumar
Journal:  J Immunol       Date:  2011-05-20       Impact factor: 5.422

6.  NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice.

Authors:  Holly L Rosenzweig; Kellen Galster; Emily E Vance; Joe Ensign-Lewis; Gabriel Nunez; Michael P Davey; James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-09       Impact factor: 4.799

7.  NOD2 signaling contributes to host defense in the lungs against Escherichia coli infection.

Authors:  Balamayooran Theivanthiran; Sanjay Batra; Gayathriy Balamayooran; Shanshan Cai; Koichi Kobayashi; Richard A Flavell; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2012-04-30       Impact factor: 3.441

8.  Identification of MDP (muramyl dipeptide)-binding key domains in NOD2 (nucleotide-binding and oligomerization domain-2) receptor of Labeo rohita.

Authors:  Jitendra Maharana; Banikalyan Swain; Bikash R Sahoo; Manas R Dikhit; Madhubanti Basu; Abhijit S Mahapatra; Pallipuram Jayasankar; Mrinal Samanta
Journal:  Fish Physiol Biochem       Date:  2012-12-20       Impact factor: 2.794

9.  Interferon gamma boosts the nucleotide oligomerization domain 2-mediated signaling pathway in human dendritic cells in an X-linked inhibitor of apoptosis protein and mammalian target of rapamycin-dependent manner.

Authors:  Tünde Fekete; Gabor Koncz; Brigitta Szabo; Andrea Gregus; Eva Rajnavölgyi
Journal:  Cell Mol Immunol       Date:  2015-11-02       Impact factor: 11.530

10.  Retinal astrocytes pretreated with NOD2 and TLR2 ligands activate uveitogenic T cells.

Authors:  Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.